Complex Effects of Naturally Occurring Mutations in the JAK3 Pseudokinase Domain: Evidence for Interactions between the Kinase and Pseudokinase Domains
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The structure of Janus kinases (JAKs) is unique among protein tyrosine kinases in having tandem, nonidentical kinase and pseudokinase domains. Despite its conservation in evolution, however, the function of the pseudokinase domain remains poorly understood. Lack of JAK3 expression results in severe combined immunodeficiency (SCID). In this study, we analyze two SCID patients with mutations in the JAK3 pseudokinase domain, which allows for protein expression but disrupts the regulation of the kinase activity. Specifically, these mutant forms of JAK3 had undetectable kinase activity in vitro but were hyperphosphorylated both in patients' Epstein-Barr virus-transformed B cells and when overexpressed in COS7 cells. Moreover, reconstitution of cells with these mutants demonstrated that, although they were constitutively phosphorylated basally, they were unable to transmit cytokine-dependent signals. Further analysis showed that the isolated catalytic domain of JAK3 was functional whereas either the addition of the pseudokinase domain or its deletion from the full-length molecule reduced catalytic activity. Through coimmunoprecipitation of the isolated pseudokinase domain with the isolated catalytic domain, we provide the first evidence that these two domains interact. Furthermore, whereas the wild-type pseudokinase domain modestly inhibited kinase domain-mediated STAT5 phosphorylation, the patient-derived mutants markedly inhibited this phosphorylation. We thus conclude that the JAK3 pseudokinase domain is essential for JAK3 function by regulating its catalytic activity and autophosphorylation. We propose a model in which this occurs via intramolecular interaction with the kinase domain and that increased inhibition of kinase activity by the pseudokinase domain likely contributes to the disease pathogenesis in these two patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lin, J.-X., Migone, T.-S., Tseng, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90141-8 · Cited by 752
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
Migone, T.-S., Lin, J.-X., Cereseto, A., Mulloy, J. C., O'Shea, J. J., Franchini, G., & Leonard, W. J. (1995) · Science · doi:10.1126/science.7604283 · Cited by 557
Self-citationWilks, A. F., Harpur, A. G., Kurban, R. R., Ralph, S. J., Zürcher, G., & Ziemiecki, A. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.2057 · Cited by 528 · cited 2×
“JAKs are structurally unique among metazoan PTKs in having a C-terminal catalytic domain immediately preceded by another putative domain with many features of a tyrosine kinase catalytic domain, referred to as the Janus homology 2 (JH2) domain (9, 14, 44).”
BackgroundJak-STAT Signaling Induced by the v- abl oncogene
Danial, N. N., Pernis, A., & Rothman, P. B. (1995) · Science · doi:10.1126/science.7569929 · Cited by 325
Cited by
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
Self-citationO'Shea, J. J., Gadina, M., & Schreiber, R. D. (2002) · Cell · doi:10.1016/s0092-8674(02)00701-8 · Cited by 1,119
Self-citationYamaoka, K., Saharinen, P., Pesu, M., Holt, V. E., Silvennoinen, O., & O'Shea, J. J. (2004) · Genome Biology · doi:10.1186/gb-2004-5-12-253 · Cited by 635
Self-citationActivation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD
Baas, A. F. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg292 · Cited by 385
Kovanen, P. E., & Leonard, W. J. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00203.x · Cited by 360
Cell biology of IL-7, a key lymphotrophin
Jiang, Q., Li, W. Q., Aiello, F. B., Mazzucchelli, R., Asefa, B., Khaled, A. R., & Durum, S. K. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.004 · Cited by 342
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia
Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072182 · Cited by 334
Inborn Errors of Human JAKs and STATs
Casanova, J.-L., Holland, S. M., & Notarangelo, L. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.03.016 · Cited by 320
Self-citationSaharinen, P., & Silvennoinen, O. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205156200 · Cited by 318
Activating alleles of JAK3 in acute megakaryoblastic leukemia
Walters, D. K., Mercher, T., Gu, T.-L., O'Hare, T., Tyner, J. W., Loriaux, M., Goss, V. L., Lee, K. A., Eide, C. A., Wong, M. J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.06.002 · Cited by 317
A new modality for immunosuppression: targeting the JAK/STAT pathway
O'Shea, J. J., Pesu, M., Borie, D. C., & Changelian, P. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1441 · Cited by 303
Self-citationUngureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C.-F., Neubert, T. A., Skoda, R. C., Hubbard, S. R., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2099 · Cited by 276
Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2413 · Cited by 266
Therapeutic targeting of Janus kinases
Pesu, M., Laurence, A., Kishore, N., Zwillich, S. H., Chan, G., & O'Shea, J. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00644.x · Cited by 231
“Although the pseudokinase domain itself lacks catalytic activity, this domain has critical functions in regulating catalytic activity (25, 26).”
BackgroundSelf-citationAutoinhibition of Jak2 Tyrosine Kinase Is Dependent on Specific Regions in Its Pseudokinase Domain
Saharinen, P., Vihinen, M., & Silvennoinen, O. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-06-0342 · Cited by 216
Signaling by Type I and II cytokine receptors: ten years after
Gadina, M., Hilton, D., Johnston, J. A., Morinobu, A., Lighvani, A., Zhou, Y.-J., Visconti, R., & O'Shea, J. J. (2001) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00228-4 · Cited by 206
Self-citationThe use of structural biology in Janus kinase targeted drug discovery
L. Alicea-Velazquez, N., & J. Boggon, T. (2011) · Current Drug Targets · doi:10.2174/138945011794751528 · Cited by 53
Metadata
- Authors
- Chen, M., Cheng, A., Candotti, F., Zhou, Y.-J., Hymel, A., Fasth, A., Notarangelo, L. D., & O'Shea, J. J.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2000-02-01
- Volume
- 20
- Issue
- 3
- Pages
- 947-956
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2102709092
- Cited by
- 136
- References
- 4
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.